A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs DFD 01 (Primary) ; Corticosteroid
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Promius Pharma
- 14 Feb 2018 Planned number of patients changed from 75 to 50.
- 14 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 14 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.